

## Bart Scheerder

### Short Biography:

Bart started in 2003 as a clinical research associate (CRA) for an academic contract research organization affiliated with the UMCG, traveling throughout Europe and working with many different hospitals in different therapeutic areas. He then worked as clinical project manager, managing investigator initiated studies, as well as industry sponsored clinical trials as a full service CRO. In 2013 he started as business developer with a focus on data and biobanks. He currently has a focus on data science (artificial intelligence, machine learning, big data and e-health) and is affiliated to the UMCG Innovation Center and the Data Science Center in Health (DASH). He is also president of the Dutch Clinical Research Foundation and president of the Dutch Association of Contract Research Organizations. His activities focus on connecting our researchers and our science to an extensive network in private industry and develop innovative public private partnerships to achieve UMCG's strategic goals.

### Abstract:

The synergy between artificial intelligence (AI), data science, and nuclear medicine has opened new frontiers in healthcare, promising to redefine diagnostics and therapies. The dynamic landscape of AI and data science applications in nuclear medicine and the multiple challenges involved in bringing these innovations to the market puts us as university medical center at a cross roads: do we continue along our known path or tumble down the rabbit hole and see how AI driven innovation could serve our patients and us?

In this lecture, I won't bore you with farsighted examples of what the potential could be. Certainly, this is something that by now, everyone is all but too familiar with. What I want to do is discuss some of the constraints we see in terms of regulatory compliance, ethical considerations, and data privacy concerns and discuss how and why we must overcome these, to engage in meaningful collaborative endeavors among researchers, clinicians, regulators, and industry stakeholders. (Only) together, we can navigate the complex landscape of AI and data science innovations in nuclear medicine for our ultimate goal: to deliver precise, timely, and individualized diagnostics and therapies for our patients, paving the way for a future where innovative technologies redefine the boundaries of care.